IRIDEX (NASDAQ:IRIX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a report issued on Friday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Down 1.0 %

Shares of NASDAQ IRIX opened at $1.02 on Friday. The business has a 50-day simple moving average of $1.16 and a two-hundred day simple moving average of $1.49. IRIDEX has a 52 week low of $0.78 and a 52 week high of $3.25. The company has a market cap of $17.12 million, a P/E ratio of -1.52 and a beta of 0.74. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Thursday, March 27th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $12.70 million during the quarter, compared to analyst estimates of $12.80 million. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.